Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 23;13:898. doi: 10.1038/s41467-022-28566-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022, corrected publication 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a Impact of LZTR1 knockdown on cell proliferation in nine primary melanoma cell lines and two normal human melanocyte lines (NBMEL). Key mutations are indicated (Supplementary Table 7). Bar plots depict mean fold change between the 3rd and 6th day after infection with LZTR1 shRNA (numbered), as compared to control (scrambled) shRNA (C) with error bars indicating 95% confidence intervals. b Western blots with anti-LZTR1 antibodies showing the efficacy of LZTR1 knockdown, related to panel a. This experiment was reproduced twice with LZTR1 shRNA 1 and shRNA 2, compared to control. c Cell proliferation (left) and LZTR1 expression (right) of a sun-exposed melanoma cell line that lost one LZTR1 allele in response to genomic modification by different CRISPR-Cas9 sgRNAs targeting LZTR1. Bar plots depict fold change between the 3rd and 6th day after infection with sgRNA 5. Data represent one experiment. Bars in a, c represent the mean of triplicate wells with error bars indicating 95% confidence intervals. Actin levels in b and c show protein loading. Cell lines are indicated above all plots in a–c and colored according to their origin: acral melanoma (blue), sun-exposed melanoma (red), normal melanocyte (gray). NBMEL newborn melanocytes, WT wildtype. Source data are provided as a Source Data file.